Tagged with B

Global A new book by two pharma industry experts offers the first truly global perspective on the complexities of market access.   Even the most innovative drug is useless if patients cannot afford or access it. As pharmaceutical innovation advances, market access strategies – determining who gets a drug, at what…

Saudi Arabia Extending not only lifespan, but “healthspan,” and ensuring people live healthier lives for longer is moving beyond purely clinical settings. Experts gathered last week at the Global Healthspan 2025 Summit in Riyadh, Saudi Arabia focused on factors such as lifestyle, the role of virtual tools, and a more holistic approach…

USA Since Christopher Viehbacher took the reins of Biogen in 2022, he has launched a USD 1 billion cost-cutting and priority refocusing plan, made significant deals, and launched the firm’s Alzheimer’s drug Legembi. But snags slowing the uptake of the Eisai-partnered med and the fall in sales of its multiple sclerosis…

Saudi Arabia Three leading lights from biopharma, policy, and research come together in Riyadh to discuss the current treatment and prevention landscape for Alzheimer’s disease.   As people live longer, the threat of age-related diseases deepens. Alzheimer’s, one of the cruellest such diseases, therefore represents an increasingly urgent public health challenge in…

Saudi Arabia Amr Kenawi, General Manager at Zimmer Biomet in Saudi Arabia, shares his perspective on the country’s evolving healthcare landscape and the company’s role in supporting Vision 2030. Kenawi discusses Zimmer Biomet’s strategic shift from product distribution to offering integrated musculoskeletal solutions, the introduction of cutting-edge technologies like robotics, and the…

Saudi Arabia Saudi Arabia is rapidly shaping its future as a global research powerhouse, channelling unprecedented resources into translational research, clinical trials, and genomics. At the heart of this transformation is the Saudi NIH, driving 13 key research priorities and forging strategic global partnerships. Speaking at The Global Healthspan Summit (GHS 2025)…

Saudi Arabia Despite groundbreaking advances in longevity science, one fundamental challenge remains: how to turn wellness into a scalable, investable industry. Speaking at The Global Healthspan Summit (GHS 2025) in Riyadh, Dr. Mehmood Khan, CEO of the Hevolution Foundation, argues that without a structured economic model, healthy longevity will remain an untapped…

Saudi Arabia Dr Vineta Bhalla, Partner and Chief Medical Officer at Deloitte Middle East, brings a wealth of experience from her background as a clinician, public health expert, and healthcare leader in both Singapore and the UK. Bhalla shares her insights into Saudi Arabia’s healthcare transformation, highlighting the Kingdom’s methodical approach to…

Global HEOR is transforming healthcare decision-making by evaluating treatment costs, patient quality of life, and overall value, helping stakeholders make informed choices. ISPOR’s new “HEOR Explained” website simplifies these complex concepts to promote wider understanding and application of real-world evidence and ultimately drive more effective and sustainable healthcare.   In today’s…

Japan Japan’s amended Cannabis Control Law now permits the development and medical use of cannabis-derived drugs, particularly CBD-based treatments, while simultaneously criminalizing self-use of smokable cannabis products. Writing in the February 2024 edition of DIA’s Global Forum magazine, Toshi Tominaga of Keio University explains why, despite aligning with evolving international regulations,…

China China’s position as one of the leading global sources and recipients of biopharmaceutical innovation is inarguable. However, in the new Year of the Snake, geopolitical and economic uncertainties are swirling, calling some to question the role that the country can continue to play in global health. Despite these challenging times,…

Denmark As tensions rise over US-EU trade, will the weight-loss drug Ozempic become an unexpected bargaining chip? Stan Jackson explores the risks of leveraging GLP-1s in economic negotiations.   You can always tell when a blockbuster drug has entered the cultural zeitgeist. It’s around the time you start to hear the…